CHICAGO, United States – Media OutReach – December 4, 2023 –
VinBraina leading AI HealthTech company based in Vietnam, funded by Vingroup, participated in the largest medical meetings and exhibitions in North America,
RSNA 2023. Unveiling two impactful AI-centric solutions at the event: DrAid™ Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid™ Oncology Diagnosis and Treatment, VinBrain is achieving major milestones in innovation, aiming to save more lives and advance precision care for all.
Steven Truong, founder and CEO of VinBrain, has impressed professionals around the world with revolutionary solutions.
RSNA 2023: Leading change in AI for diagnosis, treatment, care and interoperability
The technical exhibits at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Illinois, USA, concluded after four immersive days, November 26-29, marked by exciting and groundbreaking advances in many health care subspecialties.
Proud to be one of 113 new exhibitors at RSNA, VinBrain marks the first time that a Vietnamese AI HealthTech startup has participated in this largest global healthcare conference.
“VinBrain’s scalable portfolio of AI solutions is rapidly being adopted by physicians,” said
Professor Dr Gregory MooreAssociate Fellow Center for Artificial Intelligence and Medical Imaging (AIMI) at Stanford University School of Medicine, former Vice President of Microsoft Health Global and Google Cloud Healthcare.
VinBrain’s presence at RSNA goes beyond just presenting the company; it’s about learning and aligning with others in our shared mission to provide high-quality diagnostic radiology care more efficiently and safely.
VinBrain has attracted attention with revolutionary new elements in radiology AI and streamlining hospital operations.
At the exclusive launch at 10:30 a.m. CT on November 27, the company launched two revolutionary new solutions, encompassing
DrAid™ Enterprise data solution: centralization, transformation, intelligence; and DrAid™ Oncology Diagnosis and Treatment (D&T).
Accelerate interoperability and rationalization,
DrAid™ Enterprise Data Solution (EDS) It is hoped to lead the transformation of healthcare toward precision care. EDS brings a big data-based knowledge engine whose core is “transforming massive raw medical data into actionable knowledge and insights,” said Steven Truong, founder and CEO of VinBrain.
EDS is capable of automatically generating multilingual reports in over 25 languages. It helps doctors summarize exam history and highlight differences between reports and medical images. Additionally, it provides personalized electrical medical record analysis and intelligent EMR search. For hospital operators, EDS provides real-time insights through intuitive multiple dashboards and AI predictive analytics, enabling data-driven decisions for resource allocation. The excitement extends to DrAid™ Copilot – an AI-powered medical virtual assistant that helps healthcare professionals search, extract data and improve productivity through natural language interaction. All EDS modules are organized under the secure, centralized Data Lake and data management infrastructure, converting data in structured formats and massive silos into a repository for world-class security and durable, centralized storage for purposes operational and R&D.
D&T Oncology, on the other hand, it proves wider adoption of AI for more accurate diagnosis and better treatment decisions for the most complex diseases in human history. VinBrain is one of the few pioneers in the world to develop a screening and treatment support platform to strengthen the fight against liver and rectal cancer, two of the 10 deadliest cancers in the world.
Innovative AI-based solutions, CT Liver Cancer D&T and MRI Rectal Cancer D&T, reveal the intricacies of cancer classification, localization and measurement, enabling early detection and offering hope of saving more lives . Notably, CT Liver Cancer D&T can detect hepatocellular carcinoma (HCC), the most common liver malignancy. This solution uses a novel method based on wavelet radiomic features from multiphase CT images for HCC screening. The study of this method was recently published in Nature Scientific Reports just ahead of RSNA 2023, coinciding with CT Liver Cancer D&T’s advancement to the final stage of the ASEAN Digital Innovation 2023 Awards.
Oncology D&T uses all SOTAs, including nnUnet, ConvNeXt, and attention techniques. It is trained and validated on large, high-quality datasets, confirmed by experienced radiologists. By providing comprehensive information, it helps oncologists evaluate treatment and surgical options such as surgical resection and transarterial chemoembolization (TACE) and total mesorectal excision (TME). The goal of D&T in oncology is to extend life expectancy for a healthier life for patients and work as a second reader, while improving workflow triage.
Guided by a quality-first approach throughout our 4-year journey, VinBrain prioritizes our strategic collaboration with renowned institutions like Stanford University. As a guest speaker, Dr. Michael C. Muelly, Clinical Assistant Professor of Radiology at Stanford University, VinBrain Medical Partner shared:
“I enjoyed spending time on the product launch. It’s great to see what VinBrain is working on, and I’m very excited to see what’s to come. Opportunities for AI to make an impact important in the world and in medicine are huge. Viet Nam could be the perfect place where this happens, starts and spreads from there.”
Dr. Michael C. Muelly, VinBrain Medical Partner, shared his perspectives on clinical practices and solution values during the product launch at RSNA 2023.
DrAid™’ can be easily integrated and deployed in many systems (PACS, HIS, RIS, EMR…), with the option of cloud or on-premises availability via the DrAid™ appliance. The VinBrain team collaborates with NVIDIA every two weeks to leverage NVIDIA’s 48 GPUs in addition to MONAI and Tensor RT. DrAid™ adheres to HIPAA and NIST standards using Azure, ensuring robust privacy and security.
At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved and high-TB burden areas through DrAid™ for TB Screening (CXR Screening). This cost-effective solution enables large-scale screenings for approximately 10.6 million people suspected of tuberculosis, garnering praise from other exhibitors.
Keep learning and growing!
As artificial intelligence continues to advance in radiology, such participation is valuable experience for VinBrain in all aspects, including research and development, innovation and commercialization capability. Through fruitful in-person discussions with nearly 500 visitors over four days, as well as meeting 670 industry leaders at the exhibitions, VinBrain and its flagship product – DrAid™ gained a lot of knowledge to strengthen the strategy of global expansion and are poised to make a significant impact in the SEA, US, India, UK/EU and Middle East markets between 2024 and 2027.
Hashtag: #WineBrain
The issuer is solely responsible for the content of this announcement.
